Novo hits back at rivals with cut-price Wegovy subscriptions
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
Newsletters and Deep Dive digital magazine
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.
Editor's Picks
Newsletters and Deep Dive
digital magazine